By Industry | By Industry Segment | By Services and Suppliers | By Location | By Hotbed | Profile Search

Company Profile


Hemispherx Biopharma Inc. 

One Penn Center
1617 JFK Boulevard
Philadelphia  Pennsylvania  19103  U.S.A.
Phone: 215-988-0080 Fax: 215-988-1739


Company News
Hemispherx (HEB) Bolsters Manufacturing And Scientific Capabilities Through Key Consulting And Management Appointments 7/19/2016 8:18:19 AM
Hemispherx (HEB) Details Strategic Growth Plan, Transparency Commitment 7/14/2016 7:18:02 AM
Hemispherx (HEB) Updates The Status Of The Alferon Manufacturing Facility 7/11/2016 8:09:38 AM
Hemispherx (HEB) Enters Into Settlement Agreements Dismissing All Pending Shareholder Derivative Litigation, Resolving Disputes With Insurance Carriers, And Obtaining Commitments Of $3.5 Million In Payments To Company 6/9/2016 7:30:58 AM
Hemispherx (HEB): Dr. William M. Mitchell Publishes Article Titled, “Efficacy Of Rintatolimod In The Treatment Of Chronic Fatigue Syndrome/Myalgic Encephalomyelitis (CFS/ME)” In Expert Review Of Clinical Pharmacology 6/7/2016 2:13:22 PM
Hemispherx (HEB) Obtains A Comprehensive Carter Omnibus Assignment Of Intellectual Property 6/6/2016 4:01:03 PM
Hemispherx (HEB) Renews Sales, Marketing, Distribution And Supply Agreement With GP Pharm 5/31/2016 8:21:29 AM
Hemispherx (HEB) Amends And Restates Agreement With MyTomorrows For The Early Access Program For Rintatolimod In Europe 5/23/2016 10:00:50 AM
Hemispherx (HEB) Announces Financial Results For The Three Months Ended March 31, 2016 5/17/2016 10:03:21 AM
Hemispherx (HEB) Announces Conference Call To Provide Quarterly Business Update On May 17, 2016 5/12/2016 10:28:21 AM